T.J. Herzog

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial

M.A. Powell, Line Bjørge, Lyndsay Willmott et al. · Annals of Oncology · 2024 · 102 citations · Full text

Medicine, Gynecology, Oncology +15

LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)

B.J. Monk, A. Oaknin, David M. O’Malley et al. · Annals of Oncology · 2024 · 35 citations

Medicine, Oncology, Pharmacotherapy +16

Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer.

B.J. Monk, T.J. Herzog, Stuart Kaye et al. · Journal of Clinical Oncology · 2011 · 21 citations

Medicine, Oncology, Pharmacology +17

Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube

Peter G. Rose, Richard D. Drake, Patricia S. Braly et al. · Journal of Clinical Oncology · 2009 · 19 citations

Medicine, Oncology, Pharmacotherapy +16

Fallopian Tube Removal: “stic-Ing” it to Ovarian Cancer: What Is the Utility of Prophylactic Tubal Removal?

T.J. Herzog, Helen E. Dinkelspiel · Current Oncology · 2013 · 18 citations · Full text

Medicine, Gynecology, Surgery +10